November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback